​

Atea Pharmaceuticals (AVIR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

AVIR Stock Forecast

Atea Pharmaceuticals (AVIR) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $6.88, with a high of $6.88 and a low of $6.88. This represents a 13.72% increase from the last price of $6.05.

High: $6.88 Avg: $6.88 Low: $6.88 Last Closed Price: $6.05

AVIR Stock Rating

Atea Pharmaceuticals stock's rating consensus is Hold, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 1 Buy (25.00%), 2 Hold (50.00%), 1 Sell (25.00%), and 0 Strong Sell (0.00%).

Hold
Total 4 0 1 2 1 Strong Sell Sell Hold Buy Strong Buy

AVIR Price Target Upside V Benchmarks

TypeNameUpside
StockAtea Pharmaceuticals13.72%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$6.05$6.05$6.05
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-21--3
Feb, 26-21--3
Jan, 26-21--3
Dec, 25-21--3
Nov, 25-11--2
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 12, 2024Matthew HarrisonMorgan Stanley$6.88$3.35105.37%13.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2024Morgan StanleyEqual-Weightupgrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$1.46$-1.39$-1.63$-2.00$-1.94--
Avg Forecast$0.45$-1.31$-1.41$-1.80$-1.58$-1.59$0.20
High Forecast$0.57$-1.31$-1.39$-1.74$-1.25$-1.40$0.20
Low Forecast$0.33$-1.31$-1.42$-1.89$-2.04$-1.79$0.20
Surprise %224.44%6.11%15.60%11.11%22.78%--

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$351.37M------
Avg Forecast$258.98M$240.98M-$68.29M$7.08M$7.86M$237.90M
High Forecast$310.19M$289.17M-$68.29M$7.08M$7.86M$237.90M
Low Forecast$204.49M$192.78M-$68.29M$7.08M$7.86M$237.90M
Surprise %35.67%------

Net Income Forecast

$-500M $-200M $100M $400M $700M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$121.19M$-115.91M$-135.96M$-168.38M$-158.35M--
Avg Forecast$743.25M$583.63M$-117.37M$-151.57M$-155.71M$-132.99M$16.68M
High Forecast$940.62M$780.68M$-115.96M$-145.21M$-104.65M$-116.78M$16.68M
Low Forecast$545.88M$386.58M$-118.79M$-157.94M$-170.24M$-149.19M$16.68M
Surprise %-83.69%-119.86%15.83%11.09%1.69%--

AVIR Forecast FAQ

Is Atea Pharmaceuticals stock a buy?

Atea Pharmaceuticals stock has a consensus rating of Hold, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 1 Buy, 2 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Atea Pharmaceuticals is a neutral investment for most analysts.

What is Atea Pharmaceuticals's price target?

Atea Pharmaceuticals's price target, set by 4 Wall Street analysts, averages $6.88 over the next 12 months. The price target range spans from $6.88 at the low end to $6.88 at the high end, suggesting a potential 13.72% change from the previous closing price of $6.05.

How does Atea Pharmaceuticals stock forecast compare to its benchmarks?

Atea Pharmaceuticals's stock forecast shows a 13.72% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Atea Pharmaceuticals over the past three months?

  • March 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 66.67% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Atea Pharmaceuticals’s EPS forecast?

Atea Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.59, marking a -18.04% decrease from the reported $-1.94 in 2025. Estimates for the following years are.

What is Atea Pharmaceuticals’s revenue forecast?

Atea Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $7.86M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for.

What is Atea Pharmaceuticals’s net income forecast?

Atea Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-133M, representing a -16.02% decrease from the reported $-158M in 2025. Projections indicate .